A Single-arm, Multicenter Prospective Study to Evaluate the Diagnostic Performance of PROSTest in Men With PSA ≥ 3ng/ml Using Biopsy as the Sole Ground Truth
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This prospective observational study will enroll men referred for prostate biopsy due to elevated PSA and/or abnormal digital rectal examination, with or without pre-biopsy MRI. Peripheral blood will be collected prior to biopsy for PROSTest analysis. Biopsy histopathology will serve as the reference standard. PROSTest results will be analyzed blinded to pathology.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Podwyższony poziom PSA i/lub nieprawidłowe badanie palpacyjne prostaty
✗ Disqualifies
- •Wcześniejsze rozpoznanie raka prostaty
Simplified criteria — AI translation
Trial details
- Minimum age
- 45 Years
- Maximum age
- 80 Years
- Last updated (source)
- August 21, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
Wren Laboratories
Branford, United States
Trial contact
Mark Kidd, PhD
Tracy Auster, BS
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/22/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.